gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Nephrogenic Systemic Fibrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davenport, MS; Gagnier, JJ; MacEachern, MP; Shankar, PR; Singer, L; Woolen, SA | 1 |
| Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA | 1 |
| Alison, D; Bacigalupo, L; Billiouw, JM; Boffa, JJ; Campioni, P; Deray, G; Devos, D; Ferreiros, J; Glowacki, F; Hannedouche, T; Maes, B; Marti-Bonmati, L; Rigothier, C; Rouviere, O; Vrtovsnik, F | 1 |
1 review(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Topics: Contraindications, Drug; Contrast Media; Gadolinium; Glomerular Filtration Rate; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk; Severity of Illness Index; United States; United States Food and Drug Administration | 2020 |
1 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).
Topics: Acute Kidney Injury; Aged; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2013 |
1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds | 2010 |